Literature DB >> 6861866

Bioavailability and saturation of the presystemic metabolism of oral lorcainide therapy initiated in three different dose regimens.

W K Amery, J Heykants, K Bruyneel, R Terryn.   

Abstract

The feasibility of giving a supplementary starting dose of the antiarrhythmic drug lorcainide, in order to minimalize the impact of the extensive, but saturable first-pass metabolism, was evaluated. Twenty-five adult patients were given 100 mg lorcainide tablets according to one of 3 different dosage schedules: Eight patients took one tablet at 0, 12 and 24 h, 8 took 1 tablet at 0, 1, 12 and 24 h and 9 took 1 tablet at 0, 2, 12 and 24 h. Levels of lorcainide and its metabolite, nor-lorcainide, during treatment were determined by gas-liquid chromatography. The results show that giving a second tablet 1 or 2 h after the first may produce faster saturation of the pre-systemic metabolism of lorcainide in the liver.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861866     DOI: 10.1007/bf00609895

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Clinical pharmacokinetics of antiarrhythmic drugs.

Authors:  D C Harrison; P J Meffin; R A Winkle
Journal:  Prog Cardiovasc Dis       Date:  1977 Nov-Dec       Impact factor: 8.194

2.  Lorcainide. I. Saturable presystemic elimination.

Authors:  E Jähnchen; H Bechtold; W Kasper; F Kersting; H Just; J Heykants; T Meinertz
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

3.  Lorcainide. II. Plasma concentration-effect relationship.

Authors:  T Meinertz; W Kasper; F Kersting; H Just; H Bechtold; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

Review 4.  Antiarrhythmic agents and their use in therapy.

Authors:  L S Dreifus; J Morganroth
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

5.  Disposition and antiarrhythmic effect of lorcainide.

Authors:  U Klotz; P Müller-Seydlitz; P Heimburg
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-04

6.  Simultaneous gas chromatographic determination of lorcainide hydrochloride and three of its principal metabolites in biological samples.

Authors:  R Woestenborghs; M Michiels; J Heykants
Journal:  J Chromatogr       Date:  1979-10-11

7.  Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.

Authors:  U Klotz; P Müller-Seydlitz; P Heimburg
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

Review 8.  Lorcainide (R 15 889), a first review.

Authors:  W K Amery; J J Heykants; R Xhonneux; G Towse; P Oettel; D A Gough; P A Janssen
Journal:  Acta Cardiol       Date:  1981       Impact factor: 1.718

  8 in total
  2 in total

Review 1.  Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  C e Eiriksson; R N Brogden
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 2.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.